AEON BIOPHARMA INC
AEONNYSE AMERICAN🏆 #4769 by market capEarnings Nov 13US Equity
$0.27▲ $0.02 (+7.24%)
Pre-market · at closeTrack AEON
Get earnings, price moves & breaking news on Telegram
24h▲ 7.2%
7d▲ 11.6%
14d▲ 6.3%
30d▲ 0.8%
ytd▼ 77.6%
1y▼ 71.8%
🏦Market Cap
$10M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $0.27 – $0.27
- 52-Week Range
- $0.18 – $1.45
- Volume (shares)
- 2,721
- Avg Volume (shares)
- —
- Shares Outstanding
- 37.2M
- Next Earnings
- 2026-11-13
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-3.58
- Dividend Yield
- —
- Dilution (1yr)
- +2079.9%
AEON BIOPHARMA INC
AEONFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$13M▼ −117.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$17M▼ −14.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
12.1M▲ +2079.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$33M▼ −$20M YoY
StockOtter · stockotter.spaceAbout AEON BIOPHARMA INC
AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervical dystonia, and gastroparesis. The entity, originally known as ALPHAEON Corporation, adopted the name AEON Biopharma, Inc. in December 2019. Established in 2012, the company maintains its principal operations from Newport Beach, California.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst Ratings
ⓘConsensus
Buy
10 analysts
Strong Buy2
Buy7
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.